Tesamorelin
Tesamorelin API
Tesamorelin yog cov tshuaj peptide hluavtaws, lub npe tag nrho yog ThGRF (1-44)NH₂, uas yog ib qho kev loj hlob hormone tso tawm hormone (GHRH) analog. Nws txhawb nqa lub anterior pituitary kom zais kev loj hlob hormone (GH) los ntawm simulating qhov kev txiav txim ntawm endogenous GHRH, yog li indirectly nce qib ntawm insulin-zoo li kev loj hlob yam 1 (IGF-1), coj ib tug series ntawm cov txiaj ntsig hauv metabolism thiab kho cov ntaub so ntswg.
Tam sim no, Tesamorelin tau pom zoo los ntawm FDA rau kev kho mob HIV-txog li lipodystrophy, tshwj xeeb tshaj yog rau kev txo qis hauv plab visceral rog tsub zuj zuj (visceral adipose ntaub so ntswg, VAT). Nws kuj tau kawm dav dav rau ** kev tiv thaiv kev laus, cov kab mob metabolic, kab mob tsis muaj dej cawv fatty siab (NAFLD / NASH) ** thiab lwm yam kev lag luam, uas qhia dav dav daim ntawv thov kev cia siab.
Mechanism ntawm kev ua
Tesamorelin yog 44-amino acid peptide nrog cov qauv zoo ib yam li GHRH ntuj. Nws mechanism ntawm kev txiav txim yog:
Ua kom GHRH receptor (GHRHR) los txhawb lub anterior pituitary kom tso GH.
Tom qab GH nce siab, nws ua rau lub siab thiab cov ntaub so ntswg ib puag ncig kom nce IGF-1 synthesis.
GH thiab IGF-1 sib koom ua ke hauv cov roj metabolism, cov protein synthesis, kho cell thiab kho pob txha ceev.
Nws tsuas yog ua rau visceral fat decomposition (fat mobilization) thiab tsis tshua muaj txiaj ntsig rau cov rog subcutaneous.
Piv nrog rau kev txhaj tshuaj ncaj qha ntawm GH, Tesamorelin txhawb nqa GH tso tawm los ntawm cov txheej txheem endogenous, uas yog ze rau ntawm lub cev lub cev thiab zam kev tsis zoo tshwm sim los ntawm GH ntau dhau, xws li dej tuav thiab insulin tsis kam.
Kev tshawb nrhiav thiab kev kho mob ua tau zoo
Qhov ua tau zoo ntawm Tesamorelin tau raug txheeb xyuas los ntawm ntau qhov kev sim tshuaj, tshwj xeeb tshaj yog nyob rau hauv cov chaw hauv qab no:
1. HIV-related lipodystrophy (FDA-pom zoo qhia)
Tesamorelin tuaj yeem txo qis VAT hauv plab (qhov nruab nrab txo qis ntawm 15-20%);
Nce IGF-1 qib thiab txhim kho lub cev metabolic xeev;
Txhim kho lub cev zoo thiab txo cov kev puas siab puas ntsws cuam tshuam nrog kev faib tawm rog;
Nws tsis cuam tshuam rau subcutaneous rog txheej, pob txha ceev lossis cov leeg nqaij.
2. Non-alcoholic steatohepatitis (NASH) thiab daim siab fibrosis
Cov kev sim tshuaj ntsuam xyuas tau pom tias Tesamorelin tuaj yeem txo cov roj hauv siab (MRI-PDFF imaging);
Nws yuav tsum txhim kho hepatocyte insulin rhiab heev;
Nws muaj txiaj ntsig tshwj xeeb rau cov neeg mob HIV thiab NAFLD, thiab muaj peev xwm tiv thaiv kab mob metabolic dav dav.
3. Metabolic syndrome thiab insulin tsis kam
Tesamorelin txo qis cov qib triglyceride thiab rog plab;
Txhim kho HOMA-IR Performance index thiab pab txhim kho insulin tsis kam;
Cov kev tshawb fawb tau pom tias nws tuaj yeem txhim kho cov leeg nqaij protein synthesis muaj peev xwm, uas muaj txiaj ntsig zoo rau cov neeg laus lossis cov kab mob ntev ntev.
API ntau lawm thiab kev tswj kom zoo
Tesamorelin API muab los ntawm peb pawg Gentolex tau txais cov qib siab peptide synthesis thev naus laus zis (SPPS) thiab tsim nyob rau hauv GMP ib puag ncig. Nws muaj cov yam ntxwv hauv qab no:
Purity ≥99% (HPLC)
Tsis muaj endotoxin, hnyav hlau, residual solvent nrhiav tau tsim nyog
Amino acid ib ntus thiab cov qauv kev pom zoo los ntawm LC-MS / NMR
Muab gram-theem rau kilogram-theem customized ntau lawm
